# Tarsus Pharmaceuticals, Inc.

**TARS**

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001819790

**A**

**strongest fifth of 370 graded peers in healthcare**

rank 17 of 370; percentile 4.3; sampling error 2.5 points; lower is stronger




**A, the bull**



| Scoreboard | |
|---|---|
| **Profitability** | B<br>percentile 37.1 |
| **Solvency** | B<br>percentile 30.6 |
| **Growth and financing** | B<br>percentile 22.8 |
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $562.2M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered; fortress balance sheet |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Feb 23, 2026<br>243 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026 |
| **Last close** | $68.17<br>2026-10-23; market equity $3.0B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 23, 2026*

We are a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. We launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of Demodex blepharitis, in August 2023 after receiving U.S. Food and Drug Administration ("FDA") approval in July 2023. Demodex blepharitis is caused by the infestation of Demodex mites.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 37.1** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (11.5%) | (6.6%) | 37.1 | 809 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 30.6** | | | | | |
| Twelve-month failure probability | 0.03% | 0.07% | 19.1 | 247 | 2026-06-30 |
| Altman Z double-prime | 2.84 | (0.33) | 26.2 | 754 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *EBITDA must exceed $100,000* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | |
| Current ratio | 3.85x | 2.94x | 46.6 | 836 | 2025-12-31 |
| **Growth and financing, sleeve percentile 22.8** | | | | | |
| Revenue growth, three-year compound | 159.5% | 10.1% | 2.4 | 413 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | |
| Asset growth, three years | 35.1% | 2.1% | 13.6 | 702 | 2025-12-31 |
| Net share issuance, one year | 10.9% | 2.5% | 52.4 | 634 | 2026-02-17 |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Fortress balance sheet | cash minus debt is 111,202,000 USD; Altman Z is not used |

## Among 370 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 12 | Penumbra Inc. (PEN) | 3.0 | A | |
| 13 | Lemaitre Vascular Inc. (LMAT) | 3.3 | A | |
| 14 | Electromed, Inc. (ELMD) | 3.5 | A | fortress balance sheet |
| 15 | Tactile Systems Technology Inc. (TCMD) | 3.8 | A | fortress balance sheet |
| 16 | Corcept Therapeutics Inc. (CORT) | 4.1 | A | fortress balance sheet |
| 17 | Tarsus Pharmaceuticals, Inc. (TARS) | 4.3 | A | fortress balance sheet |
| 18 | Ideaya Biosciences, Inc. (IDYA) | 4.6 | A | |
| 19 | Vericel Corp. (VCEL) | 4.9 | A | |
| 20 | Biomarin Pharmaceutical Inc. (BMRN) | 5.1 | A | |
| 21 | Neurocrine Biosciences Inc. (NBIX) | 5.4 | A | |
| 22 | Crispr Therapeutics AG (CRSP) | 5.7 | A | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## What the price implies

*at the 2026-10-23 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 24.9% | 7.7% | 62 |
| Distance from 52-week high | (24.9%) | (31.4%) | 58 |
| EBIT to enterprise value | (2.5%) | (1.5%) | 46 |
| Free cash flow yield | (0.7%) | (1.0%) | 51 |
| Book value to price | 0.12 | 0.28 | 29 |
| Sales to price | 0.15 | 0.30 | 34 |
| Composite equity issuance, five years | 76.1% | 20.5% | 73 |
| Relative strength against the sector, log excess return | 0.01 | (0.14) | 62 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | pass |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $204.6M |
| Operating cash flow, four quarters | $74.2M |
| Months of runway | not finite |
| Days since last periodic filing | 79 (10-Q received Aug 6, 2026) |
| Median daily dollar volume, 63 sessions | $48.8M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | operating income | us-gaap:OperatingIncomeLoss | -$71.0M | 2025-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 2 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$64.4M | 2025-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 3 | income tax | us-gaap:IncomeTaxExpenseBenefit | $2.1M | 2025-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 4 | total debt | us-gaap:LongTermDebt | $72.4M | 2025-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 5 | book equity | us-gaap:StockholdersEquity | $343.4M | 2025-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 6 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $183.6M | 2025-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 7 | total debt | us-gaap:LongTermDebt | $71.8M | 2024-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 8 | book equity | us-gaap:StockholdersEquity | $224.5M | 2024-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 9 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $94.8M | 2024-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 10 | net income | us-gaap:NetIncomeLoss | -$66.4M | 2025-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 11 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$12.5M | 2025-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 12 | assets | us-gaap:Assets | $562.2M | 2025-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 13 | assets | us-gaap:Assets | $377.0M | 2024-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 14 | current assets | us-gaap:AssetsCurrent | $522.8M | 2025-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 15 | current liabilities | us-gaap:LiabilitiesCurrent | $135.7M | 2025-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 16 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$426.6M | 2025-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 17 | liabilities | us-gaap:Liabilities | $218.7M | 2025-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 18 | depreciation amortization | us-gaap:Depreciation | $855,000 | 2025-12-31 | 2026-02-23 | 10-K | 26-000019 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 19 | operating income | us-gaap:OperatingIncomeLoss | -$143.2M | 2023-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 20 | interest expense | us-gaap:InterestExpense | $3.3M | 2023-12-31 | 2024-02-27 | 10-K | 24-000018 |
| 21 | revenue | us-gaap:Revenues | $451.4M | 2025-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 22 | revenue | us-gaap:Revenues | $183.0M | 2024-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 23 | revenue | us-gaap:Revenues | $17.4M | 2023-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 24 | revenue | us-gaap:Revenues | $25.8M | 2022-12-31 | 2025-02-25 | 10-K | 25-000011 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $9.9M | 2025-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$83.0M | 2024-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 27 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.6M | 2024-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$117.5M | 2023-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 29 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.5M | 2023-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 30 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$49.0M | 2022-12-31 | 2025-02-25 | 10-K | 25-000011 |
| 31 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $506,000 | 2022-12-31 | 2025-02-25 | 10-K | 25-000011 |
| 32 | current assets | us-gaap:AssetsCurrent | $356.7M | 2024-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 33 | current liabilities | us-gaap:LiabilitiesCurrent | $80.6M | 2024-12-31 | 2026-02-23 | 10-K | 26-000019 |
| 34 | assets | us-gaap:Assets | $265.5M | 2023-12-31 | 2025-02-25 | 10-K | 25-000011 |
| 35 | assets | us-gaap:Assets | $227.9M | 2022-12-31 | 2024-02-27 | 10-K | 24-000018 |
| 36 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 42,557,492 | 2026-02-17 | 2026-02-23 | 10-K | 26-000019 |
| 37 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 38,377,178 | 2025-02-19 | 2025-02-25 | 10-K | 25-000011 |